M
Mirum Pharmaceuticals, Inc. (MIRM)
NGM – Real Time Price. Currency in USD
106.88
+0.71 (0.67%)
At close: May 12, 2026, 4:00 PM EDT
104.50
-2.38 (-2.23%)
After-hours: May 12, 2026, 5:13 PM EDT
Find any stock by ticker or company name

NGM – Real Time Price. Currency in USD
106.88
+0.71 (0.67%)
At close: May 12, 2026, 4:00 PM EDT
104.50
-2.38 (-2.23%)
After-hours: May 12, 2026, 5:13 PM EDT
No Data
There are no news for this stock.
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 2.09 | 6.05 | 10 | |
| Quick ratio | 1.99 | 5.63 | 10 | |
| Debt to Equity | 1.34 | 0.30 | 5.0 | |
| Debt to Assets | 0.36 | 1.04 | 6.0 | |
| Interest coverage | -17.47 | -16.91 | 1.0 | |
| Weighted average score | 6.4 | |||
| METRIC | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | 77M | 186M | 337M | 521M | 570M |
| Gross Profit | 64M | 139M | 255M | 421M | 463M |
| Operating Income | -131M | -109M | -88M | -22M | -70M |
| Net Income | -136M | -163M | -88M | -23M | -799M |
| EBITDA | -128M | -98M | -64M | 2M | -45M |
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | 29.06 | -546.67 | 5.5 |
| Next quarter | 29.17 | -1430 | 5.5 |
| Current year | 29.41 | -3192.46 | 5.5 |
| Next year | 20.53 | 98.03 | 10 |
| Weighted average score | 6.6 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | 7.35 | -13689.78 | -13329.99 | -4296.57 | 2.0 |
| Y/Y | 43.28 | -5283.62 | -4376.66 | -11359.88 | 3.3 |
| 3y average | 92.45 | 33.06 | 43.21 | 214.04 | 10 |
| 5y average | 315.8 | 11.26 | 23.36 | 120.55 | 9.3 |
| Weighted average score | 6.2 | ||||
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | None | 1.0 |
| Intangible assets | None | 1.0 |
| Switching costs | None | 1.0 |
| Network effect | None | 1.0 |
| Economies of scale | None | 1.0 |
| Weighted average score | 1.0 | |
Cash reserves $324.9M barely cover the upcoming debt maturities $323.8M
Total current assets $569.4M exceed Total current liabilities $272.8M, highlighting excellent liquidity
Debt-to-equity ratio (1.3) is near the industry average, reflecting balanced leverage
Interest coverage ratio (-17.5x) is dangerously low, suggesting debt repayment risks
Negative free cash flow -$229.4M limits the company's ability to reinvest or pay down debt